466 related articles for article (PubMed ID: 17950857)
1. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies.
Wenzel S; Wilbraham D; Fuller R; Getz EB; Longphre M
Lancet; 2007 Oct; 370(9596):1422-31. PubMed ID: 17950857
[TBL] [Abstract][Full Text] [Related]
2. Bimosiamose, an inhaled small-molecule pan-selectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics: a randomized, double-blind, placebo-controlled clinical cross-over-trial.
Beeh KM; Beier J; Meyer M; Buhl R; Zahlten R; Wolff G
Pulm Pharmacol Ther; 2006; 19(4):233-41. PubMed ID: 16140027
[TBL] [Abstract][Full Text] [Related]
3. Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme.
Krug N; Hohlfeld JM; Kirsten AM; Kornmann O; Beeh KM; Kappeler D; Korn S; Ignatenko S; Timmer W; Rogon C; Zeitvogel J; Zhang N; Bille J; Homburg U; Turowska A; Bachert C; Werfel T; Buhl R; Renz J; Garn H; Renz H
N Engl J Med; 2015 May; 372(21):1987-95. PubMed ID: 25981191
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.
Franciosi LG; Diamant Z; Banner KH; Zuiker R; Morelli N; Kamerling IM; de Kam ML; Burggraaf J; Cohen AF; Cazzola M; Calzetta L; Singh D; Spina D; Walker MJ; Page CP
Lancet Respir Med; 2013 Nov; 1(9):714-27. PubMed ID: 24429275
[TBL] [Abstract][Full Text] [Related]
5. Inhaled vs subcutaneous effects of a dual IL-4/IL-13 antagonist in a monkey model of asthma.
Tomkinson A; Tepper J; Morton M; Bowden A; Stevens L; Harris P; Lindell D; Fitch N; Gundel R; Getz EB
Allergy; 2010 Jan; 65(1):69-77. PubMed ID: 19796211
[TBL] [Abstract][Full Text] [Related]
6. Effect of IVL745, a VLA-4 antagonist, on allergen-induced bronchoconstriction in patients with asthma.
Norris V; Choong L; Tran D; Corden Z; Boyce M; Arshad H; Holgate S; O'Connor B; Millet S; Miller B; Rohatagi S; Kirkesseli S
J Allergy Clin Immunol; 2005 Oct; 116(4):761-7. PubMed ID: 16210048
[TBL] [Abstract][Full Text] [Related]
7. Intranasal GSK2245035, a Toll-like receptor 7 agonist, does not attenuate the allergen-induced asthmatic response in a randomized, double-blind, placebo-controlled experimental medicine study.
Siddall H; Quint D; Pandya H; Powley W; Shabbir S; Hohlfeld JM; Singh D; Lee L
PLoS One; 2020; 15(11):e0240964. PubMed ID: 33166307
[TBL] [Abstract][Full Text] [Related]
8. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
[TBL] [Abstract][Full Text] [Related]
9. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction.
Leff JA; Busse WW; Pearlman D; Bronsky EA; Kemp J; Hendeles L; Dockhorn R; Kundu S; Zhang J; Seidenberg BC; Reiss TF
N Engl J Med; 1998 Jul; 339(3):147-52. PubMed ID: 9664090
[TBL] [Abstract][Full Text] [Related]
10. Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness after allergen challenge.
Louw C; Williams Z; Venter L; Leichtl S; Schmid-Wirlitsch C; Bredenbroker D; Bardin PG
Respiration; 2007; 74(4):411-7. PubMed ID: 16954654
[TBL] [Abstract][Full Text] [Related]
11. Effects of the Toll-like receptor 7 (TLR7) agonist, AZD8848, on allergen-induced responses in patients with mild asthma: a double-blind, randomised, parallel-group study.
Leaker BR; Singh D; Lindgren S; Almqvist G; Eriksson L; Young B; O'Connor B
Respir Res; 2019 Dec; 20(1):288. PubMed ID: 31856838
[TBL] [Abstract][Full Text] [Related]
12. Mast cell tryptase release and asthmatic responses to allergen increase with regular use of salbutamol.
Swystun VA; Gordon JR; Davis EB; Zhang X; Cockcroft DW
J Allergy Clin Immunol; 2000 Jul; 106(1 Pt 1):57-64. PubMed ID: 10887306
[TBL] [Abstract][Full Text] [Related]
13. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial.
Papi A; Corradi M; Pigeon-Francisco C; Baronio R; Siergiejko Z; Petruzzelli S; Fabbri LM; Rabe KF
Lancet Respir Med; 2013 Mar; 1(1):23-31. PubMed ID: 24321801
[TBL] [Abstract][Full Text] [Related]
14. The inhibitory effect of nebulized albuterol on the early and late asthmatic reactions and increase in airway responsiveness provoked by inhaled allergen in asthma.
Twentyman OP; Finnerty JP; Holgate ST
Am Rev Respir Dis; 1991 Oct; 144(4):782-7. PubMed ID: 1928949
[TBL] [Abstract][Full Text] [Related]
15. Effect of an inhaled adenosine A2A agonist on the allergen-induced late asthmatic response.
Luijk B; van den Berge M; Kerstjens HA; Postma DS; Cass L; Sabin A; Lammers JW
Allergy; 2008 Jan; 63(1):75-80. PubMed ID: 17944983
[TBL] [Abstract][Full Text] [Related]
16. Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459.
Pettipher R; Hunter MG; Perkins CM; Collins LP; Lewis T; Baillet M; Steiner J; Bell J; Payton MA
Allergy; 2014 Sep; 69(9):1223-32. PubMed ID: 24866478
[TBL] [Abstract][Full Text] [Related]
17. A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5'-monophosphate in asthmatic patients.
Taylor DA; Jensen MW; Kanabar V; Engelstätter R; Steinijans VW; Barnes PJ; O'Connor BJ
Am J Respir Crit Care Med; 1999 Jul; 160(1):237-43. PubMed ID: 10390406
[TBL] [Abstract][Full Text] [Related]
18. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response.
Bryan SA; O'Connor BJ; Matti S; Leckie MJ; Kanabar V; Khan J; Warrington SJ; Renzetti L; Rames A; Bock JA; Boyce MJ; Hansel TT; Holgate ST; Barnes PJ
Lancet; 2000 Dec 23-30; 356(9248):2149-53. PubMed ID: 11191543
[TBL] [Abstract][Full Text] [Related]
19. Effects of JNJ-40929837, a leukotriene A4 hydrolase inhibitor, in a bronchial allergen challenge model of asthma.
Barchuk W; Lambert J; Fuhr R; Jiang JZ; Bertelsen K; Fourie A; Liu X; Silkoff PE; Barnathan ES; Thurmond R
Pulm Pharmacol Ther; 2014 Oct; 29(1):15-23. PubMed ID: 25018015
[TBL] [Abstract][Full Text] [Related]
20. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge.
Scheerens H; Arron JR; Zheng Y; Putnam WS; Erickson RW; Choy DF; Harris JM; Lee J; Jarjour NN; Matthews JG
Clin Exp Allergy; 2014 Jan; 44(1):38-46. PubMed ID: 24131304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
